Biohaven’s protein degrader is promising in early IgAN trial, heads straight to Phase 3
Interim Phase 1 data on Biohaven’s protein degrader are strong enough that the biotech is planning to move the drug straight into pivotal trials in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
